Recent Developments in the General Anesthesia Drugs Market In June 2023, Milla Pharmaceuticals’ generic variant of Precedex, dexmedetomidine hydrochloride injection 4mcg/mL in 50mL and 100mL, was ...

Below is Validea's guru fundamental report for TEVA PHARMACEUTICAL INDUSTRIES LTD (ADR) (TEVA). Of the 22 guru strategies we follow, TEVA rates highest using our Twin Momentum Investor model based ...

It acts by targeting PARP2. It was also under development for unspecified respiratory disorders. Teva Pharmaceutical Industries (Teva) discovers, develops, manufactures, and commercializes generic and ...

It was also under development for the treatment of solid tumors and urothelial carcinoma (UC). Teva Pharmaceutical Industries (Teva) discovers, develops, manufactures, and commercializes generic and ...

On December 17, Teva ... from generic bendamustine products, as well as declining demand for Copaxone in the US and Europe. This is included due to the launch of more effective drugs to combat ...

NORTHVALE, NJ - Elite Pharmaceuticals, Inc. (OTCQB: ELTP), a specialty pharmaceutical company with a market capitalization of $571.58 million, announced the release of a generic version of the ADHD ...

Elite Pharmaceuticals announced the launch of its generic version of Vyvanse® (Lisdexamfetamine Disylate) in various strengths, targeting the ADHD treatment market. The product, which is marketed ...

(OTCQB: ELTP), a specialty pharmaceutical company with a market capitalization of $571.58 million, announced the release of a generic version of the ADHD medication Vyvanse® (Lisdexamfetamine ...

(OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of Vyvanse ...